Ozempic Side Effects UK: Diabetes & Off-Label Weight Loss — What to Know

Ozempic contains semaglutide, the same active ingredient as Wegovy, but at lower doses (0.5mg, 1mg, and 2mg weekly) and with a different MHRA-approved indication. In the UK, Ozempic is licensed specifically for the treatment of type 2 diabetes mellitus in adults, to improve blood glucose control.

Wegovy vs Ozempic — The Key Difference: - Ozempic (0.5mg, 1mg, 2mg): Licensed for type 2 diabetes - Wegovy (2.4mg): Licensed for chronic weight management

Although both contain semaglutide, they are approved for distinct purposes. The higher dose in Wegovy was specifically studied and approved for weight loss in people without diabetes (or with obesity-related conditions).

Off-Label Use in the UK: Ozempic has been widely prescribed off-label for weight loss in the UK, particularly during periods when Wegovy was in short supply (a significant shortage affected the UK from 2023–2025). While off-label prescribing is legal and sometimes clinically appropriate, it has raised serious concerns: - Supply shortages affecting diabetic patients who genuinely need Ozempic for glycaemic control - MHRA guidance has consistently emphasised that Ozempic should be prioritised for its approved indication - The NHS does not fund Ozempic for weight loss; off-label prescriptions are typically private

Who Is Ozempic Appropriate For in the UK? Primarily, adults with type 2 diabetes who need improved blood glucose management, particularly those who also have cardiovascular disease (Ozempic has a proven cardioprotective benefit in this group).

*This article is for educational purposes only. Always consult your GP or diabetes specialist before starting any semaglutide product.*

The side effect profile of Ozempic is broadly similar to Wegovy, as both contain semaglutide. The main difference is that Ozempic uses lower doses, which may result in a somewhat more tolerable initial experience — though not always.

The most commonly reported gastrointestinal side effects include:

• •Nausea — the most frequent, reported by up to 40% of users in trials. Typically most pronounced in the first 4–8 weeks and during dose escalation.
• •Vomiting — reported by approximately 9–24% of users depending on dose and study
• •Diarrhoea — can be troublesome particularly in the early weeks
• •Constipation — affects a similar proportion to diarrhoea; some patients oscillate between the two
• •Abdominal discomfort — bloating, cramping, and a sensation of early fullness are common
• •Dyspepsia (indigestion) — belching and heartburn are frequently reported

Dose Escalation for Ozempic: Ozempic uses a gentler starting protocol than Wegovy: - Weeks 1–4: 0.25mg weekly (this is a starter dose only, not a therapeutic dose) - From week 5: 0.5mg weekly - After at least 4 weeks at 0.5mg, can escalate to 1mg if additional glycaemic control needed - The 2mg dose is available for those requiring further improvement

Management Strategies: The same practical strategies that help with Wegovy apply here: smaller meals, avoiding fatty foods, staying well hydrated, timing the injection for evenings, and using ginger or peppermint for mild nausea. These approaches are described in detail in our Mounjaro side effects guide.

*If side effects are severe or persistent, always consult your prescriber rather than stopping the medication abruptly.*

A critically important distinction between Ozempic and weight-loss-focused GLP-1 medications is the context in which it is used. People with type 2 diabetes are often on multiple medications, and certain combinations significantly increase the risk of hypoglycaemia (low blood sugar).

Ozempic Alone: Semaglutide, as a GLP-1 receptor agonist, has a glucose-dependent mechanism — it only stimulates insulin release when blood glucose is elevated. This means that on its own, it has a low risk of causing hypoglycaemia.

Ozempic Combined with Insulin or Sulphonylureas: The risk picture changes dramatically when Ozempic is combined with: - Insulin (any type) — when Ozempic reduces appetite and food intake, the pre-existing insulin dose may become too high, causing dangerous blood sugar drops - Sulphonylureas (e.g. gliclazide, glipizide, glibenclamide) — these drugs stimulate insulin release regardless of blood glucose level, creating genuine hypoglycaemia risk when combined with Ozempic

Signs of Hypoglycaemia to Recognise: - Shakiness, trembling, or weakness - Cold sweats and clamminess - Rapid or irregular heartbeat (palpitations) - Confusion, difficulty concentrating, or slurred speech - Pallor (pale skin) - Hunger or nausea - In severe cases: loss of consciousness

What to Do: - If conscious: consume fast-acting carbohydrate (e.g. glucose tablets, 150ml of fruit juice, or sugary drink) - Follow with a longer-acting carbohydrate (e.g. a biscuit or slice of bread) - If unconscious: call 999 immediately

Managing the Risk: If you start Ozempic alongside insulin or a sulphonylurea, your GP or diabetes team should review and likely reduce your insulin or sulphonylurea dose proactively. Discuss this explicitly at your review appointment.

*Never adjust your diabetes medications without consulting your healthcare team.*

Two specific concerns that arise more frequently in the Ozempic context — as opposed to pure weight-loss GLP-1 use — are diabetic retinopathy progression and the cosmetic/physiological phenomenon colloquially known as 'Ozempic face'.

Diabetic Retinopathy: The SUSTAIN-6 cardiovascular outcomes trial for Ozempic revealed a somewhat unexpected finding: patients taking semaglutide had a higher rate of diabetic retinopathy complications compared to placebo, despite better overall glycaemic control.

This is thought to be a rapid normalisation effect — when blood glucose falls quickly after years of elevated levels, the retinal blood vessels can be stressed. This is not unique to Ozempic; it has been observed with any treatment that achieves rapid glycaemic improvement in patients with pre-existing retinopathy.

What This Means in Practice: - Before starting Ozempic, ensure you have had a diabetic eye screening (these are offered routinely through the NHS Diabetic Eye Screening Programme) - Discuss with your diabetes team if you have existing retinopathy — the risk-benefit balance needs careful consideration - Continue attending annual eye screening appointments throughout treatment

'Ozempic Face' and Muscle Loss: This colloquial term refers to the facial volume loss that can accompany significant and rapid weight loss on GLP-1 medications. It is not a drug-specific effect but rather a consequence of: - Loss of subcutaneous facial fat as the body mobilises fat stores - Potential contribution from muscle loss (sarcopenia) if protein intake is inadequate during weight loss

To minimise these effects: - Prioritise adequate protein intake (aim for at least 1.2–1.6g per kg of body weight daily) - Incorporate resistance training to preserve lean muscle mass - Lose weight at a moderate pace — very rapid weight loss accelerates facial volume changes

*Consult your GP or diabetes specialist for personalised guidance. Eye health monitoring is particularly important for people with type 2 diabetes taking Ozempic.*

As with all GLP-1 receptor agonists, Ozempic carries a class-level risk of certain serious side effects. These are the same as those described for Wegovy and Mounjaro — pancreatitis, gallbladder disease, and thyroid C-cell concerns — and the same warning signs apply.

Cardiovascular Benefits: Ozempic has an important distinction not shared by some other weight loss medications: it has a proven cardioprotective benefit in people with type 2 diabetes and established cardiovascular disease. The SUSTAIN-6 and PIONEER-6 trials demonstrated significant reductions in major adverse cardiovascular events (MACE). This is a primary reason why Ozempic — specifically — is preferred in this patient group.

Regular Monitoring for Ozempic Users: Your GP or diabetes team should be monitoring: - HbA1c (every 3–6 months initially, then annually when stable) - Renal function — GLP-1 agonists generally have a positive effect but kidneys need monitoring, particularly during illness or dehydration - Body weight — to assess treatment response - Diabetic eye screening — annually as part of the NHS programme - Blood pressure — often improves with weight loss and glycaemic control

Ozempic Supply and the Off-Label Debate: The MHRA, NHS, and Diabetes UK have all issued guidance regarding Ozempic supply prioritisation. If you have type 2 diabetes and are having difficulty obtaining your Ozempic prescription due to shortages, contact your GP or pharmacist — pharmacists are required to contact prescribers when Ozempic is unavailable so alternative arrangements can be made.

Report Side Effects: Report any suspected Ozempic side effects via the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk.

*This article is for informational purposes only and does not constitute medical advice. Ozempic must be prescribed by a qualified healthcare professional. Discuss all questions about your diabetes management with your GP or specialist.*